Hisamitsu Pharmaceutical Co Inc
TSE:4530
Hisamitsu Pharmaceutical Co Inc
Other Long-Term Assets
Hisamitsu Pharmaceutical Co Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hisamitsu Pharmaceutical Co Inc
TSE:4530
|
Other Long-Term Assets
¥11.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Other Long-Term Assets
¥450.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Other Long-Term Assets
¥479.1B
|
CAGR 3-Years
40%
|
CAGR 5-Years
34%
|
CAGR 10-Years
11%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Other Long-Term Assets
¥229B
|
CAGR 3-Years
53%
|
CAGR 5-Years
43%
|
CAGR 10-Years
16%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Other Long-Term Assets
¥133.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
13%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Other Long-Term Assets
¥107.5B
|
CAGR 3-Years
16%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
Hisamitsu Pharmaceutical Co Inc
Glance View
In the bustling landscape of Japanese pharmaceutical companies, Hisamitsu Pharmaceutical Co., Inc. stands out with its pioneering spirit and deep-rooted dedication to health and wellness. Founded in 1847, the company has evolved over a century and a half, transitioning from a modest establishment selling herbal medicines to a globally recognized manufacturer of pain-relief products. At the core of Hisamitsu's operations is its flagship product, the transdermal patch, featuring the SALONPAS brand as its crown jewel. This innovative delivery system allows active medicinal ingredients to penetrate the skin, addressing pain at its source effectively and efficiently. As global demand for non-invasive pain relief grows, Hisamitsu leverages its expertise in transdermal technology, continuously innovating and expanding its product line to cater to diverse consumer needs. Hisamitsu's success hinges on a solid blend of cutting-edge research, consistent quality, and strategic marketing prowess. By investing heavily in R&D, the company not only enhances its existing product offerings but also explores new therapeutic areas, ensuring a pipeline poised for future growth. Besides Japan, Hisamitsu's market presence extends across the Americas, Europe, and Asia, with international sales contributing significantly to its revenue stream. The company is adept at navigating intricate regulatory landscapes and varying consumer preferences to establish its footprint globally. This strategic expansion, coupled with a relentless commitment to quality, enables Hisamitsu to sustain its profitability while fulfilling its mission of delivering comfort and improved quality of life to people around the world.
See Also
What is Hisamitsu Pharmaceutical Co Inc's Other Long-Term Assets?
Other Long-Term Assets
11.8B
JPY
Based on the financial report for Nov 30, 2024, Hisamitsu Pharmaceutical Co Inc's Other Long-Term Assets amounts to 11.8B JPY.
What is Hisamitsu Pharmaceutical Co Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
3%
Over the last year, the Other Long-Term Assets growth was 13%. The average annual Other Long-Term Assets growth rates for Hisamitsu Pharmaceutical Co Inc have been 10% over the past three years , 6% over the past five years , and 3% over the past ten years .
You don't have any saved screeners yet